



## **F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022**

March 2, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- [F-star Therapeutics, Inc.](#) (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under [Events and Presentations](#). To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:

US/Canada: 1-833-471-0868

International: 1-914-987-7751

United Kingdom: 800 0288438 or 0203 1070289

A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/[Events and Presentations](#) section on the F-star Therapeutics website.

### **About F-star Therapeutics, Inc.**

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star's proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

For more information visit our [website](#) and follow us on [LinkedIn](#) and [Twitter](#).

### **For further information, please contact:**

#### **For investor inquiries**

##### **Lindsey Trickett**

VP Investor Relations & Communications

+1 240 543 7970

[lindsey.trickett@fstar.com](mailto:lindsey.trickett@fstar.com)

#### **John Fraunces**

Managing Director

LifeSci Advisors LLC

+1 917 355 2395

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)

#### **For media inquiries**

##### **Helen Shik**

Shik Communications LLC

+1 617-510-4373

[helen@shikcommunications.com](mailto:helen@shikcommunications.com)